Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 975 entries
Sorted by: Best Match Show Resources per page
Data processing pipeline for serial femtosecond crystallography at SACLA

pipeline programs

Nakane T, Joti Y, Yabashi M.
GSID: qTYff_8kHKsJ
T Nakane, Y Joti, K Tono, M Yabashi… - Journal of applied …, 2016 - scripts.iucr.org

… Since users might want to copy pipeline outputs to their home institution for analysis by their own programs, the use of a standard, widely adopted compression algorithm is an advantage. Our benchmark tests showed that compression at level...

Cite
Nakane, T., Joti, Y., Tono, K., Yabashi, M., Nango, E., Iwata, S., ... & Nureki, O. (2016). Data processing pipeline for serial femtosecond crystallography at SACLA. Journal of applied crystallography, 49(3), 1035-1041.
Nakane, Takanori, et al. "Data processing pipeline for serial femtosecond crystallography at SACLA." Journal of applied crystallography 49.3 (2016): 1035-1041.
Copy Download .nbib Format: MLA
Application of the homology method for quantification of low-attenuation lung region inpatients with and without COPD.

International journal of chronic obstructive pulmonary disease

Nishio M, Nakane K, Tanaka Y.
PMID: 27660430
Int J Chron Obstruct Pulmon Dis. 2016 Sep 06;11:2125-2137. doi: 10.2147/COPD.S110504. eCollection 2016.

BACKGROUND: Homology is a mathematical concept that can be used to quantify degree of contact. Recently, image processing with the homology method has been proposed. In this study, we used the homology method and computed tomography images to quantify...

Cite
Nishio M, Nakane K, Tanaka Y. Application of the homology method for quantification of low-attenuation lung region inpatients with and without COPD. Int J Chron Obstruct Pulmon Dis. 2016;11:2125-2137doi: 10.2147/COPD.S110504.
Nishio, M., Nakane, K., & Tanaka, Y. (2016). Application of the homology method for quantification of low-attenuation lung region inpatients with and without COPD. International journal of chronic obstructive pulmonary disease, 112125-2137. https://doi.org/10.2147/COPD.S110504
Nishio, Mizuho, et al. "Application of the homology method for quantification of low-attenuation lung region inpatients with and without COPD." International journal of chronic obstructive pulmonary disease vol. 11 (2016): 2125-2137. doi: https://doi.org/10.2147/COPD.S110504
Nishio M, Nakane K, Tanaka Y. Application of the homology method for quantification of low-attenuation lung region inpatients with and without COPD. Int J Chron Obstruct Pulmon Dis. 2016 Sep 06;11:2125-2137. doi: 10.2147/COPD.S110504. eCollection 2016. PMID: 27660430; PMCID: PMC5019166.
Copy Download .nbib Format: NLM
Inhibition of Glucan Synthesis by Flavipin-crosslinked Casein Polymers.

Bioscience, biotechnology, and biochemistry

Hayashida O, Nakano Y, Hasumi K, Endo A.
PMID: 28862563
Biosci Biotechnol Biochem. 1997 Jan;61(5):903-904. doi: 10.1271/bbb.61.903.

Mutastein, a casein polymer that inhibits insoluble glucan synthesis by Streptococcus sobrinus, was produced when Aspergillus terreus was grown in a medium containing α-casein. In these experiments, it was shown that flavipin (3,4,5-trihydroxy-6-methyl-o-phthalaldehyde) isolated from cultures of A. terreus...

Cite
Hayashida O, Nakano Y, Hasumi K, et al. Inhibition of Glucan Synthesis by Flavipin-crosslinked Casein Polymers. Biosci Biotechnol Biochem. 1997;61(5):903-904doi: 10.1271/bbb.61.903.
Hayashida, O., Nakano, Y., Hasumi, K., & Endo, A. (1997). Inhibition of Glucan Synthesis by Flavipin-crosslinked Casein Polymers. Bioscience, biotechnology, and biochemistry, 61(5), 903-904. https://doi.org/10.1271/bbb.61.903
Hayashida, Osamu, et al. "Inhibition of Glucan Synthesis by Flavipin-crosslinked Casein Polymers." Bioscience, biotechnology, and biochemistry vol. 61,5 (1997): 903-904. doi: https://doi.org/10.1271/bbb.61.903
Hayashida O, Nakano Y, Hasumi K, Endo A. Inhibition of Glucan Synthesis by Flavipin-crosslinked Casein Polymers. Biosci Biotechnol Biochem. 1997 Jan;61(5):903-904. doi: 10.1271/bbb.61.903. PMID: 28862563.
Copy Download .nbib Format: NLM
Dexmedetomidine sedation during the nighttime reduced the incidence of postoperative atrial fibrillation in cardiovascular surgery patients after tracheal extubation.

Journal of intensive care

Narisawa A, Nakane M, Kano T, Momose N, Onodera Y, Akimoto R, Kobayashi T, Iwabuchi M, Okada M, Miura Y, Kawamae K.
PMID: 26060574
J Intensive Care. 2015 May 30;3(1):26. doi: 10.1186/s40560-015-0092-5. eCollection 2015.

BACKGROUND: Dexmedetomidine (Dex) provides sedation and analgesia by acting on central alpha-2 receptors and is suitable for use after extubation because it has little respiratory depression. Considering the sympathoinhibitory and anxiolytic action of Dex, there is the possibility that...

Cite
Narisawa A, Nakane M, Kano T, et al. Dexmedetomidine sedation during the nighttime reduced the incidence of postoperative atrial fibrillation in cardiovascular surgery patients after tracheal extubation. J Intensive Care. 2015;3(1):26doi: 10.1186/s40560-015-0092-5.
Narisawa, A., Nakane, M., Kano, T., Momose, N., Onodera, Y., Akimoto, R., Kobayashi, T., Iwabuchi, M., Okada, M., Miura, Y., & Kawamae, K. (2015). Dexmedetomidine sedation during the nighttime reduced the incidence of postoperative atrial fibrillation in cardiovascular surgery patients after tracheal extubation. Journal of intensive care, 3(1), 26. https://doi.org/10.1186/s40560-015-0092-5
Narisawa, Ayuka, et al. "Dexmedetomidine sedation during the nighttime reduced the incidence of postoperative atrial fibrillation in cardiovascular surgery patients after tracheal extubation." Journal of intensive care vol. 3,1 (2015): 26. doi: https://doi.org/10.1186/s40560-015-0092-5
Narisawa A, Nakane M, Kano T, Momose N, Onodera Y, Akimoto R, Kobayashi T, Iwabuchi M, Okada M, Miura Y, Kawamae K. Dexmedetomidine sedation during the nighttime reduced the incidence of postoperative atrial fibrillation in cardiovascular surgery patients after tracheal extubation. J Intensive Care. 2015 May 30;3(1):26. doi: 10.1186/s40560-015-0092-5. eCollection 2015. PMID: 26060574; PMCID: PMC4460695.
Copy Download .nbib Format: NLM
Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: An autopsy case report.

Oncology letters

Yamaguchi T, Seki T, Miyasaka C, Inokuchi R, Kawamura R, Sakaguchi Y, Murata M, Matsuzaki K, Nakano Y, Uemura Y, Okazaki K.
PMID: 25789013
Oncol Lett. 2015 Apr;9(4):1633-1636. doi: 10.3892/ol.2015.2934. Epub 2015 Feb 05.

Sorafenib is a multikinase inhibitor currently approved in Japan for the treatment of unresectable hepatocellular carcinoma. Interstitial pneumonia induced by sorafenib may have a fatal outcome, and therefore, has recently been the focus of many studies. The current report...

Cite
Yamaguchi T, Seki T, Miyasaka C, et al. Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: An autopsy case report. Oncol Lett. 2015;9(4):1633-1636doi: 10.3892/ol.2015.2934.
Yamaguchi, T., Seki, T., Miyasaka, C., Inokuchi, R., Kawamura, R., Sakaguchi, Y., Murata, M., Matsuzaki, K., Nakano, Y., Uemura, Y., & Okazaki, K. (2015). Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: An autopsy case report. Oncology letters, 9(4), 1633-1636. https://doi.org/10.3892/ol.2015.2934
Yamaguchi, Takashi, et al. "Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: An autopsy case report." Oncology letters vol. 9,4 (2015): 1633-1636. doi: https://doi.org/10.3892/ol.2015.2934
Yamaguchi T, Seki T, Miyasaka C, Inokuchi R, Kawamura R, Sakaguchi Y, Murata M, Matsuzaki K, Nakano Y, Uemura Y, Okazaki K. Interstitial pneumonia induced by sorafenib in a patient with hepatocellular carcinoma: An autopsy case report. Oncol Lett. 2015 Apr;9(4):1633-1636. doi: 10.3892/ol.2015.2934. Epub 2015 Feb 05. PMID: 25789013; PMCID: PMC4356407.
Copy Download .nbib Format: NLM
Circulatory power and ventilatory power over time under goal-oriented sequential combination therapy for pulmonary arterial hypertension.

Pulmonary circulation

Hirashiki A, Adachi S, Nakano Y, Kamimura Y, Shimokata S, Takeshita K, Shimizu A, Toba K, Murohara T, Kondo T.
PMID: 28597753
Pulm Circ. 2017 Apr-Jun;7(2):448-454. doi: 10.1177/2045893217703954. Epub 2017 Mar 21.

Many therapeutic options are available for patients with pulmonary arterial hypertension (PAH). However, little is known about the effects of sequential combination therapy on exercise capacity. Here we monitored exercise capacity by cardiopulmonary exercise testing (CPX) and observed the...

Cite
Hirashiki A, Adachi S, Nakano Y, et al. Circulatory power and ventilatory power over time under goal-oriented sequential combination therapy for pulmonary arterial hypertension. Pulm Circ. 2017;7(2):448-454doi: 10.1177/2045893217703954.
Hirashiki, A., Adachi, S., Nakano, Y., Kamimura, Y., Shimokata, S., Takeshita, K., Shimizu, A., Toba, K., Murohara, T., & Kondo, T. (2017). Circulatory power and ventilatory power over time under goal-oriented sequential combination therapy for pulmonary arterial hypertension. Pulmonary circulation, 7(2), 448-454. https://doi.org/10.1177/2045893217703954
Hirashiki, Akihiro, et al. "Circulatory power and ventilatory power over time under goal-oriented sequential combination therapy for pulmonary arterial hypertension." Pulmonary circulation vol. 7,2 (2017): 448-454. doi: https://doi.org/10.1177/2045893217703954
Hirashiki A, Adachi S, Nakano Y, Kamimura Y, Shimokata S, Takeshita K, Shimizu A, Toba K, Murohara T, Kondo T. Circulatory power and ventilatory power over time under goal-oriented sequential combination therapy for pulmonary arterial hypertension. Pulm Circ. 2017 Apr-Jun;7(2):448-454. doi: 10.1177/2045893217703954. Epub 2017 Mar 21. PMID: 28597753; PMCID: PMC5467935.
Copy Download .nbib Format: NLM
A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis.

Neuro-oncology practice

Furuse M, Nonoguchi N, Kuroiwa T, Miyamoto S, Arakawa Y, Shinoda J, Miwa K, Iuchi T, Tsuboi K, Houkin K, Terasaka S, Tabei Y, Nakamura H, Nagane M, Sugiyama K, Terasaki M, Abe T, Narita Y, Saito N, Mukasa A, Ogasawara K, Beppu T, Kumabe T, Nariai T, Tsuyuguchi N, Nakatani E, Kurisu S, Nakagawa Y, Miyatake SI.
PMID: 27833757
Neurooncol Pract. 2016 Dec;3(4):272-280. doi: 10.1093/nop/npv064. Epub 2016 Jan 07.

BACKGROUND: Brain radiation necrosis (BRN) can be a complication of radiotherapy for primary and secondary brain tumors, as well as head and neck tumors. Since vascular endothelial growth factor (VEGF) is also a vascular permeability factor in the brain,...

Cite
Furuse M, Nonoguchi N, Kuroiwa T, et al. A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis. Neurooncol Pract. 2016;3(4):272-280doi: 10.1093/nop/npv064.
Furuse, M., Nonoguchi, N., Kuroiwa, T., Miyamoto, S., Arakawa, Y., Shinoda, J., Miwa, K., Iuchi, T., Tsuboi, K., Houkin, K., Terasaka, S., Tabei, Y., Nakamura, H., Nagane, M., Sugiyama, K., Terasaki, M., Abe, T., Narita, Y., Saito, N., Mukasa, A., Ogasawara, K., Beppu, T., Kumabe, T., Nariai, T., Tsuyuguchi, N., Nakatani, E., Kurisu, S., Nakagawa, Y., & Miyatake, S. I. (2016). A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis. Neuro-oncology practice, 3(4), 272-280. https://doi.org/10.1093/nop/npv064
Furuse, Motomasa, et al. "A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis." Neuro-oncology practice vol. 3,4 (2016): 272-280. doi: https://doi.org/10.1093/nop/npv064
Furuse M, Nonoguchi N, Kuroiwa T, Miyamoto S, Arakawa Y, Shinoda J, Miwa K, Iuchi T, Tsuboi K, Houkin K, Terasaka S, Tabei Y, Nakamura H, Nagane M, Sugiyama K, Terasaki M, Abe T, Narita Y, Saito N, Mukasa A, Ogasawara K, Beppu T, Kumabe T, Nariai T, Tsuyuguchi N, Nakatani E, Kurisu S, Nakagawa Y, Miyatake SI. A prospective, multicentre, single-arm clinical trial of bevacizumab for patients with surgically untreatable, symptomatic brain radiation necrosis. Neurooncol Pract. 2016 Dec;3(4):272-280. doi: 10.1093/nop/npv064. Epub 2016 Jan 07. PMID: 27833757; PMCID: PMC5099992.
Copy Download .nbib Format: NLM
Collision induced state-to-state energy transfer dynamics between the 2u ((1)D2) and 2g ((1)D2) ion-pair states of I2.

Physical chemistry chemical physics : PCCP

Hoshino S, Nakano Y, Araki M, Ishiwata T, Tsukiyama K.
PMID: 27165483
Phys Chem Chem Phys. 2016 Jun 07;18(21):14292-8. doi: 10.1039/c6cp00222f. Epub 2016 May 11.

We report the first observation of collision induced state-to-state energy transfer from the 2u ((1)D2) (v2u = 3-7) ion-pair state of I2 using a perturbation facilitated optical-optical double resonance technique through the c (1)Πg∼ B (3)Π(0) hyperfine mixed double-faced...

Cite
Hoshino S, Nakano Y, Araki M, et al. Collision induced state-to-state energy transfer dynamics between the 2u ((1)D2) and 2g ((1)D2) ion-pair states of I2. Phys Chem Chem Phys. 2016;18(21):14292-8doi: 10.1039/c6cp00222f.
Hoshino, S., Nakano, Y., Araki, M., Ishiwata, T., & Tsukiyama, K. (2016). Collision induced state-to-state energy transfer dynamics between the 2u ((1)D2) and 2g ((1)D2) ion-pair states of I2. Physical chemistry chemical physics : PCCP, 18(21), 14292-8. https://doi.org/10.1039/c6cp00222f
Hoshino, Shoma, et al. "Collision induced state-to-state energy transfer dynamics between the 2u ((1)D2) and 2g ((1)D2) ion-pair states of I2." Physical chemistry chemical physics : PCCP vol. 18,21 (2016): 14292-8. doi: https://doi.org/10.1039/c6cp00222f
Hoshino S, Nakano Y, Araki M, Ishiwata T, Tsukiyama K. Collision induced state-to-state energy transfer dynamics between the 2u ((1)D2) and 2g ((1)D2) ion-pair states of I2. Phys Chem Chem Phys. 2016 Jun 07;18(21):14292-8. doi: 10.1039/c6cp00222f. Epub 2016 May 11. PMID: 27165483.
Copy Download .nbib Format: NLM
Pro198Leu missense polymorphism of the glutathione peroxidase 1 gene might be a common genetic predisposition of distal symmetric polyneuropathy and macrovascular disease in Japanese type 2 diabetic patients.

Journal of diabetes investigation

Matsuno S, Sasaki H, Yamasaki H, Yamaoka H, Ogawa K, Nakatani M, Hamanishi T, Doi A, Nakano Y, Wakasaki H, Furuta H, Nishi M, Akamizu T, Nanjo K.
PMID: 24843532
J Diabetes Investig. 2011 Nov 30;2(6):474-82. doi: 10.1111/j.2040-1124.2011.00127.x.

UNLABELLED: Aims/Introduction:  We have previously reported that the Pro198Leu missense polymorphism in the glutathione peroxidase 1 (GPx-1) gene was associated with frequent macrovascular disease (MVD). Our goal was to examine whether the GPx-1 genotype is associated with diabetic neuropathy.MATERIALS...

Cite
Matsuno S, Sasaki H, Yamasaki H, et al. Pro198Leu missense polymorphism of the glutathione peroxidase 1 gene might be a common genetic predisposition of distal symmetric polyneuropathy and macrovascular disease in Japanese type 2 diabetic patients. J Diabetes Investig. 2011;2(6):474-82doi: 10.1111/j.2040-1124.2011.00127.x.
Matsuno, S., Sasaki, H., Yamasaki, H., Yamaoka, H., Ogawa, K., Nakatani, M., Hamanishi, T., Doi, A., Nakano, Y., Wakasaki, H., Furuta, H., Nishi, M., Akamizu, T., & Nanjo, K. (2011). Pro198Leu missense polymorphism of the glutathione peroxidase 1 gene might be a common genetic predisposition of distal symmetric polyneuropathy and macrovascular disease in Japanese type 2 diabetic patients. Journal of diabetes investigation, 2(6), 474-82. https://doi.org/10.1111/j.2040-1124.2011.00127.x
Matsuno, Shohei, et al. "Pro198Leu missense polymorphism of the glutathione peroxidase 1 gene might be a common genetic predisposition of distal symmetric polyneuropathy and macrovascular disease in Japanese type 2 diabetic patients." Journal of diabetes investigation vol. 2,6 (2011): 474-82. doi: https://doi.org/10.1111/j.2040-1124.2011.00127.x
Matsuno S, Sasaki H, Yamasaki H, Yamaoka H, Ogawa K, Nakatani M, Hamanishi T, Doi A, Nakano Y, Wakasaki H, Furuta H, Nishi M, Akamizu T, Nanjo K. Pro198Leu missense polymorphism of the glutathione peroxidase 1 gene might be a common genetic predisposition of distal symmetric polyneuropathy and macrovascular disease in Japanese type 2 diabetic patients. J Diabetes Investig. 2011 Nov 30;2(6):474-82. doi: 10.1111/j.2040-1124.2011.00127.x. PMID: 24843532; PMCID: PMC4014907.
Copy Download .nbib Format: NLM
Cation-Anion Dual Sensing of a Fluorescent Quinoxalinone Derivative Using Lactam-Lactim Tautomerism.

The journal of physical chemistry. A

Nakane Y, Takeda T, Hoshino N, Sakai K, Akutagawa T.
PMID: 26014712
J Phys Chem A. 2015 Jun 18;119(24):6223-31. doi: 10.1021/acs.jpca.5b02850. Epub 2015 Jun 04.

A quinoxalinone derivative capable of lactam-lactim tautomerization was designed as a new fluorescence probe for sensing of cation (M(+) = Li(+) and Na(+)) and anion (X(-) = F(-), Cl(-), Br(-), and CH3COO(-)) in organic solvents. In THF, the minor...

Cite
Nakane Y, Takeda T, Hoshino N, et al. Cation-Anion Dual Sensing of a Fluorescent Quinoxalinone Derivative Using Lactam-Lactim Tautomerism. J Phys Chem A. 2015;119(24):6223-31doi: 10.1021/acs.jpca.5b02850.
Nakane, Y., Takeda, T., Hoshino, N., Sakai, K., & Akutagawa, T. (2015). Cation-Anion Dual Sensing of a Fluorescent Quinoxalinone Derivative Using Lactam-Lactim Tautomerism. The journal of physical chemistry. A, 119(24), 6223-31. https://doi.org/10.1021/acs.jpca.5b02850
Nakane, Yuta, et al. "Cation-Anion Dual Sensing of a Fluorescent Quinoxalinone Derivative Using Lactam-Lactim Tautomerism." The journal of physical chemistry. A vol. 119,24 (2015): 6223-31. doi: https://doi.org/10.1021/acs.jpca.5b02850
Nakane Y, Takeda T, Hoshino N, Sakai K, Akutagawa T. Cation-Anion Dual Sensing of a Fluorescent Quinoxalinone Derivative Using Lactam-Lactim Tautomerism. J Phys Chem A. 2015 Jun 18;119(24):6223-31. doi: 10.1021/acs.jpca.5b02850. Epub 2015 Jun 04. PMID: 26014712.
Copy Download .nbib Format: NLM
Impact of aldosterone-producing adenoma on cardiac structures in echocardiography.

Journal of echocardiography

Hidaka T, Shiwa T, Fujii Y, Nishioka K, Utsunomiya H, Ishibashi K, Mitsuba N, Dohi Y, Oda N, Noma K, Kurisu S, Nakano Y, Yamamoto H, Iishida T, Higashi Y, Kihara Y.
PMID: 24319340
J Echocardiogr. 2013;11:123-9. doi: 10.1007/s12574-013-0168-y. Epub 2013 Feb 05.

BACKGROUND: Primary aldosteronism (PA) is a most common cause of secondary hypertension. In PA, left ventricular hypertrophy (LVH) is more progressive than in any other cause of hypertension. Aldosterone-producing adenoma (APA) and idiopathic hyperaldosteronism (IHA) are major subtypes of...

Cite
Hidaka T, Shiwa T, Fujii Y, et al. Impact of aldosterone-producing adenoma on cardiac structures in echocardiography. J Echocardiogr. 2013;11:123-9doi: 10.1007/s12574-013-0168-y.
Hidaka, T., Shiwa, T., Fujii, Y., Nishioka, K., Utsunomiya, H., Ishibashi, K., Mitsuba, N., Dohi, Y., Oda, N., Noma, K., Kurisu, S., Nakano, Y., Yamamoto, H., Iishida, T., Higashi, Y., & Kihara, Y. (2013). Impact of aldosterone-producing adenoma on cardiac structures in echocardiography. Journal of echocardiography, 11123-9. https://doi.org/10.1007/s12574-013-0168-y
Hidaka, Takayuki, et al. "Impact of aldosterone-producing adenoma on cardiac structures in echocardiography." Journal of echocardiography vol. 11 (2013): 123-9. doi: https://doi.org/10.1007/s12574-013-0168-y
Hidaka T, Shiwa T, Fujii Y, Nishioka K, Utsunomiya H, Ishibashi K, Mitsuba N, Dohi Y, Oda N, Noma K, Kurisu S, Nakano Y, Yamamoto H, Iishida T, Higashi Y, Kihara Y. Impact of aldosterone-producing adenoma on cardiac structures in echocardiography. J Echocardiogr. 2013;11:123-9. doi: 10.1007/s12574-013-0168-y. Epub 2013 Feb 05. PMID: 24319340; PMCID: PMC3851697.
Copy Download .nbib Format: NLM
Effects of α1-Blockers for Lower Urinary Tract Symptoms and Sleep Disorders in Patients with Benign Prostatic Hyperplasia.

Lower urinary tract symptoms

Sakuma T, Sato K, Nagane Y, Mochida J, Sugimoto S, Ichinose T, Yamaguchi K, Uchiyama M, Takahashi S.
PMID: 26676294
Low Urin Tract Symptoms. 2010 Sep;2(2):119-22. doi: 10.1111/j.1757-5672.2010.00073.x. Epub 2010 Jul 05.

OBJECTIVES: We evaluated the association of lower urinary tract symptoms (LUTS) and sleep disorders (SD) in patients with benign prostatic hyperplasia (BPH). We also examined improvement of SD following the α1-blocker therapy for LUTS.METHODS: Sixty-eight male patients were enrolled...

Cite
Sakuma T, Sato K, Nagane Y, et al. Effects of α1-Blockers for Lower Urinary Tract Symptoms and Sleep Disorders in Patients with Benign Prostatic Hyperplasia. Low Urin Tract Symptoms. 2010;2(2):119-22doi: 10.1111/j.1757-5672.2010.00073.x.
Sakuma, T., Sato, K., Nagane, Y., Mochida, J., Sugimoto, S., Ichinose, T., Yamaguchi, K., Uchiyama, M., & Takahashi, S. (2010). Effects of α1-Blockers for Lower Urinary Tract Symptoms and Sleep Disorders in Patients with Benign Prostatic Hyperplasia. Lower urinary tract symptoms, 2(2), 119-22. https://doi.org/10.1111/j.1757-5672.2010.00073.x
Sakuma, Takahiro, et al. "Effects of α1-Blockers for Lower Urinary Tract Symptoms and Sleep Disorders in Patients with Benign Prostatic Hyperplasia." Lower urinary tract symptoms vol. 2,2 (2010): 119-22. doi: https://doi.org/10.1111/j.1757-5672.2010.00073.x
Sakuma T, Sato K, Nagane Y, Mochida J, Sugimoto S, Ichinose T, Yamaguchi K, Uchiyama M, Takahashi S. Effects of α1-Blockers for Lower Urinary Tract Symptoms and Sleep Disorders in Patients with Benign Prostatic Hyperplasia. Low Urin Tract Symptoms. 2010 Sep;2(2):119-22. doi: 10.1111/j.1757-5672.2010.00073.x. Epub 2010 Jul 05. PMID: 26676294.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 975 entries